Designing Of Small Molecule Inhibitors For NMPRTaseas Anticancer Leads Using Insilico Approach | 4720
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Designing of small molecule inhibitors for NMPRTaseas Anticancer leads using insilico approach

3rd World Congress on Biotechnology

Venkat Koushik Pulla, Perumal Yogeeswari and Dharmarajan Sriram

Posters: Agrotechnol

DOI: 10.4172/2155-952X.S1.020

Nicotinamide Phospho ribosyltransferase (NMPRTase) is an enzyme catalyses the biosynthesis of NAD+. It is generally expressed more in cancerous cell lines. The inhibitors targeted to NMPRTase reduce the cellular NAD+ concentration which results in apoptosis and cell death, hence can be used to treat cancer. These inhibitors could also target the NAD+ dependent enzymes like sirtuins indirectly, which were implicated in many diseases like diabetes, neurodegeneration and inflammation. Thus designing inhibitors to NMPRTase would be a good strategy to treat various disorders. In the present work, crystal structure of NMPRTase (2GVJ) with 2.1 A o resolution, was employed for the energy based pharmacophore model generation for the crystal ligand (FK866) and virtual screening was carried out using Glide docking (Schrodinger). Commercial databases were used for virtual screening.Top30 potential hits were shortlisted by comparing pharmaophore fitness, docking score and hydrogen bonds with crystal ligand. These top hits are the potential lead compounds for treating cancer and other disorders.
Venkat Koushik Pulla has completed his MSc from Sheffield Hallam University, UK. Currently he is doing PhD in Bits Pilani, Hyderabad campus. His area of interest is to design and screen the lead compounds targeted to cancer.